Antibiotic Resistance by Sequencing

About Fry Laboratories

Fry Laboratories is a private, Arizona-based diagnostics company that historically provided specialized testing services for complex conditions like Lyme disease and chronic inflammatory illnesses. Its core technology platform, RIDI™ (Rapid Infectious Disease Identification by Sequencing), uses next-generation DNA sequencing to detect bacteria, fungi, and protists. The company is currently in a transitional state, having halted routine clinical services to focus on R&D and potential partnerships for its sequencing-based diagnostic and antibiotic resistance detection technologies. Leadership includes founder Dr. Stephen E. Fry and CEO Judith Joseph.

Therapeutic Areas